CRNX
Price
$30.68
Change
+$0.02 (+0.07%)
Updated
Aug 29, 01:25 PM (EDT)
Capitalization
2.89B
69 days until earnings call
KRYS
Price
$148.57
Change
-$2.19 (-1.45%)
Updated
Aug 29, 01:28 PM (EDT)
Capitalization
4.36B
73 days until earnings call
Interact to see
Advertisement

CRNX vs KRYS

Header iconCRNX vs KRYS Comparison
Open Charts CRNX vs KRYSBanner chart's image
Crinetics Pharmaceuticals
Price$30.68
Change+$0.02 (+0.07%)
Volume$1.3K
Capitalization2.89B
Krystal Biotech
Price$148.57
Change-$2.19 (-1.45%)
Volume$500
Capitalization4.36B
CRNX vs KRYS Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. KRYS commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a StrongBuy and KRYS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (CRNX: $30.65 vs. KRYS: $150.76)
Brand notoriety: CRNX and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 90% vs. KRYS: 69%
Market capitalization -- CRNX: $2.89B vs. KRYS: $4.36B
CRNX [@Biotechnology] is valued at $2.89B. KRYS’s [@Biotechnology] market capitalization is $4.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 6 TA indicator(s) are bullish while KRYS’s TA Score has 7 bullish TA indicator(s).

  • CRNX’s TA Score: 6 bullish, 3 bearish.
  • KRYS’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а +4.25% price change this week, while KRYS (@Biotechnology) price change was +3.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.84%. For the same industry, the average monthly price growth was +15.38%, and the average quarterly price growth was +29.54%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

KRYS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (-0.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.36B) has a higher market cap than CRNX($2.89B). KRYS YTD gains are higher at: -3.766 vs. CRNX (-40.055). KRYS has higher annual earnings (EBITDA): 158M vs. CRNX (-419.62M). CRNX has more cash in the bank: 1.2B vs. KRYS (682M). KRYS has less debt than CRNX: KRYS (9.68M) vs CRNX (49.9M). KRYS has higher revenues than CRNX: KRYS (359M) vs CRNX (1.39M).
CRNXKRYSCRNX / KRYS
Capitalization2.89B4.36B66%
EBITDA-419.62M158M-266%
Gain YTD-40.055-3.7661,064%
P/E RatioN/A30.64-
Revenue1.39M359M0%
Total Cash1.2B682M175%
Total Debt49.9M9.68M515%
FUNDAMENTALS RATINGS
CRNX vs KRYS: Fundamental Ratings
CRNX
KRYS
OUTLOOK RATING
1..100
873
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
6738
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6361
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (66) in the Pharmaceuticals Major industry is in the same range as CRNX (86). This means that KRYS’s stock grew similarly to CRNX’s over the last 12 months.

KRYS's Profit vs Risk Rating (38) in the Pharmaceuticals Major industry is in the same range as CRNX (67). This means that KRYS’s stock grew similarly to CRNX’s over the last 12 months.

KRYS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as CRNX (100). This means that KRYS’s stock grew similarly to CRNX’s over the last 12 months.

KRYS's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as CRNX (63). This means that KRYS’s stock grew similarly to CRNX’s over the last 12 months.

KRYS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as CRNX (100). This means that KRYS’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXKRYS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 8 days ago
75%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 10 days ago
77%
Bearish Trend 12 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FVDKX39.41N/A
N/A
Fidelity Value Discovery K
KLGAX54.50N/A
N/A
NYLI WMC Growth Class A
MFVFX14.59N/A
N/A
MassMutual Equity Opports R4
TCIHX27.12N/A
N/A
Nuveen International Eq Idx I
NIAGX13.88N/A
N/A
Nia Impact Solutions